Total Marrow Irradiation Combined with High-Dose Melphalan for Patients with Relapsed/Refractory Multiple Myeloma: A Phase 1 Study

High dose melphalan at 200  mg/m2 (Mel200) followed by autologous stem cell transplant (ASCT) improves progression free survival in patients with multiple myeloma (MM) but is not curative. Enhancing the anti-myeloma effect of pre-transplant conditioning without increasing toxicity is therefore an important goal. With this r ationale, intensity modulated radiation therapy (IMRT) can be used to deliver a high dose of radiation to the bone marrow (total marrow irradiation, TMI) while sparing other organs.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research

Related Links:

Leukemia, Published online: 11 November 2019; doi:10.1038/s41375-019-0634-2Cytogenetic subclone formation and evolution in progressive smoldering multiple myeloma
Source: Leukemia - Category: Hematology Authors: Source Type: research
Multiple myeloma (MM) is an incurable plasma cell dyscrasia characterized by the uncontrollable proliferation of clonal plasma cells resulting in myeloma-defining events (end-organ damage and/or biomarkers of malignancy) [1]. MM constitutes a significant contributor to the global burden of hematological malignancy causing 2.1 million disability-adjusted life-years (DALYs) worldwide according to the Global Burden of Disease 2016 study [2]. During the last decades, an increase in the disease incidence has been clearly demonstrated, especially in North America, Western Europe and Australasia [2].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Anti-Tumour Treatment Source Type: research
Patients with multiple myeloma (MM) are known to be immune incompetent and experience higher incidences of infectious diseases. However, infective endocarditis (IE) is rarely observed in patients with MM and Morg...
Source: BMC Infectious Diseases - Category: Infectious Diseases Authors: Tags: Case report Source Type: research
This study strongly suggests that ASCT2 is an excellent target molecule for the treatment of malignancies, especiallyKRAS‐mutated cancers. AbstractKRAS mutations are detected in numerous human cancers, but there are few effective drugs forKRAS‐mutated cancers. Transporters for amino acids and glucose are highly expressed on cancer cells, possibly to maintain rapid cell growth and metabolism. Alanine‐serine‐cysteine transporter 2 (ASCT2) is a primary transporter for glutamine in cancer cells. In this study, we developed a novel mono clonal antibody (mAb) recognizing the extracellular domain of human ASCT2, and inves...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Publication date: Available online 9 November 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Aleeza Abbasi, Catherine Chung, Basem M. William
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 9 November 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Prajwal Dhakal, Elizabeth Lyden, Andrea Lee, Joel Michalski, Zaid S. Al-Kadhimi, Lori J. Maness, Krishna Gundabolu, Vijaya Raj BhattAbstractBackgroundThe role of obesity in prognosis of acute myeloid leukemia(AML) is debatable. Our retrospective study aimed to determine the effect of obesity on overall survival(OS) in AML.MethodsAML patients diagnosed at University of Nebraska Medical Center were divided into 3-groups based on body mass index (BMI): normal(18.5-25kg/m2) or underweight(
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 9 November 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Megan Melody, Andrew Kuykendall, David Sallman, Najla Al Ali, Ling Zhang, Chetasi Talati, Eric Padron, Kendra Sweet, Martine Extermann, Alan List, Jeffrey Lancet, Rami KomrokjiAbstractAML in elderly patients (pts) is associated with poor outcomes and often arises from antecedent hematological disorders (AHD), classified as secondary AML (sAML). In order to validate the use of somatic mutations to determine AML ontogeny in the elderly population, we identified 178 elderly (>70yo) AML pts with NexGen Sequencing data....
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 21 October 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Giulia Gabrielli, Alessandro Broccoli, Cinzia Pellegrini, Lisa Argnani, Michele Cavo, Pier Luigi Zinzani
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
AbstractHematologic malignancies include several lymphoproliferative and myeloproliferative disorders, many of which are frequently encountered in current health care settings. These malignancies frequently affect the gastrointestinal (GI) tract, either by secondary extranodal or extramedullary extension to the GI tract, or as a primary process arising in the GI tract. In fact, the GI tract may represent the most common extranodal site of involvement in many of them, such as lymphoma. Furthermore, in the current era of improved cancer treatment and advanced transplant procedures with increased survival, it has been quite c...
Source: Abdominal Imaging - Category: Radiology Source Type: research
Hyperphosphatemia is an electrolytic disorder that may be of concern in the setting of tumor lysis syndrome (TLS), rhabdomyolysis, and metabolic acidosis. Furthermore, hyperphosphatemia occurs in advanced chronic kidney disease and hypoparathyroidism. In the acute setting, such as TLS, hyperphosphatemia can lead to consider renal replacement therapy.
Source: The American Journal of Medicine - Category: General Medicine Authors: Tags: Clinical Communication to the Editor Source Type: research
More News: Biology | Intensity-Modulated Radiation Therapy | Myeloma | Radiation Therapy | Stem Cell Therapy | Stem Cells | Study | Toxicology | Transplants